Biosimilar User Fee Talks Reach Starting Line As Report Shows Growing FDA Workload
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency staff efforts dedicated to 351(k) reviews increased more than 10-fold in fiscal year 2015, Eastern Research Group says.
You may also be interested in...
FDA Sets New Goal For Biosimilar, Drug Promotion Guidances
Agency plans to issue 102 new and revised draft guidances this year, including those on use of multiple endpoints in clinical trials, 180-day exclusivity, and ANDA refuse-to-receive standards.
Biosimilar User Fee Negotiations Won't Start Until 2016
Mid-December kick-off meeting puts emerging user fee program on much later track than others.
Big Drug, Small Panel: US FDA Adcomm For Eisai/Biogen’s Leqembi Includes Only Six Voting Members
Six is the fewest number of voting experts for a drug or biologic advisory committee dating back to at least 2015, according to the Pink Sheet Performance Tracker. Agency issued two conflict-of-interest waivers for the meeting, one of which was to a site principal investigator on lecanemab and aducanumab studies but who is no longer participating in the Leqembi review.